SUBSTANCES CONSIDERED NOT TO REQUIRE CONTROL
BY SCHEDULING
4-[4-(ACETYLOXY)PHENYL]-2-
BUTANONE Feb 2005 b 1.7
AGROBACTERIUM RADIOBACTER Nov 1989 a 1
ALCOHOL, DEHYDRATED Aug 2000 b 6
ALUM May 1997 a 7.1
ALUMINIUM AMMONIUM SULFATE May 1997 a 7.1
ALUMINIUM POTASSIUM SULFATE May 1997 a 7.1
ALUMINIUM SILICATE Nov 1974 a 7.1
ALUMINIUM tris (ETHYLPHOSPHONATE) Aug 1986 a 1
AMMONIUM PHOSPHATE Nov 1974 a 7.1
AMMONIUM THIOSULPHATE Nov 1974 a 7.1
AMPROLIUM Jun 1969 a 2.3
AMYL ACETATE Nov 1974 a 7.1
-AMYLASE derived from Aspergillus niger Feb 2005 a 2.4
ANDROSTENEDIONE ALBUMEN
CONJUGATE WITH DEA DEXTRAN
ADJUNCT Jun 2004 a 2.1
ASPARTIC ACID - a 6
ASULAM May 1986 a 1
AZIMSULFURON Jun 2003 a 1.1
BACILLUS SPHAERICUS STRAIN 2362 Feb 2003 a 5.1
BACILLUS THURINGIENSIS May 1992 a 5.1
(excluding endotoxin) Jun 2003 a 2.10
BACILLUS TOYOI Aug 1980 a 2.9
BACULOVIRUS CYDIA POMONELLA Jun 2006 a 1.2
BENFLURALIN - a 1.1
BENSULFURON-METHYL Aug 1987 a 1
BENTONITE Jun 2002 a 7.1
BENZYL BENZOATE Aug 1989 a 1.3.4
BETAINE HYDROCHLORIDE Nov 1974 a 7.1
BIFENAZATE Oct 2002 a 1.9
BISMUTH SUBNITRATE Nov 1999 b, c 2.1
BIURET Nov 1974 a 2.4
BOSCALID June 2003 a 1.3
BOVINE SOMATOTROPHIN May 1992 a 2
BROMACIL Aug 1987 a 1
BROMOPROPYLATE Nov 1994 a 1
BUPIRIMATE Nov 1990 a 1
BUTAFENACIL May 2000 a 1
BUTOXYPOLYPROPYLENE GYLCOL Nov 1974 a 7.7
n-BUTYL BUTYRATE - a 7.1
n-BUTYL LACTATE - a 7.1
CARBETAMIDE Aug 1991 a 1
CARBOXIN Aug 1987 a 1
CARFENTRAZONE-ETHYL Aug 1998 a 1
CELLULASE derived from
CETYL ALCOHOL Nov 1974 a 7.1
CHAMOMILE OIL Feb 2000 a 3.1
CHINA CLAY Nov 1974 a 7.1
CHLORANTRANILIPROLE Sep 2008 a 1.2
CHLORFLUAZURON Oct 2005 a 1.2.2
CHLORFLURENOL Feb 1974 a 1.6
CHLORIDAZON May 1988 a 1
CHLOROXYLENOLS Feb 1975 a 7.8
CITRONELLA OIL Feb 2000 a 7.1
CLARY SAGE OIL Feb 2000 a 7.1
Part Part 3 - Poisons Standard 2010 | Zoe
CLOPIDOL Nov 1974 d 2.3
COBALT NAPHTHENATE - d 7.1
COLOPHONY Feb 1997 b 7.4
CROSPOVIDONE Aug 1996 a 2
CULICINOMYCES CLAVOSPORUS Nov 1982 a 5.1
CYCLAMIC ACID Nov 1971 a 7.1
CYCLOHEXANE Nov 1974 a 7.7
CYCLOHEXANOL ACETATE - a 7.7
CYROMAZINE Nov 1980 a 2
DICLAZURIL Nov 2001 a 2.3
DIETHYL CARBONATE - a 7.1
DIFLUFENICAN Feb 1987 a 1
DIKEGULAC-SODIUM Mar 1980 a 1.6
DIMETHICONE a 7.1
DIMETHYL ETHER Nov 1988 d 4
DIPHENYLAMINE Feb 1988 a 1
DIPROPYLENE GLYCOL
MONOMETHYL ETHER Nov 1987 a 4
DIURON Nov 1987 a 1
DOCUSATE SODIUM
(DIOCTYL SODIUM SULFOSUCCINATE) Feb 1970 a 7.1
2,2-DPA Nov 1989 a 1
drometrizole trisiloxane Oct 2003 a 6.4
EPSIPRANTEL Nov 1991 a 2
ETHAMETSULFURON-METHYL Nov 2000 a 1.1
ETHOPABATE Jun 1969 d 2.3
ETHYL ACETATE Nov 1974 a 7.1
ETHYL ALCOHOL Nov 1974 a 7.1
ETHYLBUTYLACETYL-
AMINOPROPRIONATE Aug 2000 a 3.4
ETHYL BUTYRATE - a 7.1
ETHYL LACTATE - a 7.1
ETOXAZOLE Oct 2003 a 1.2
FENFURAM May 1977 a 1.3.1
FENHEXAMID Feb 1999 a 1
FENOXYCARB Feb 1988 a 1
FLUFENOXURON Feb 1997 a 1
FLUMETSULAM Feb 1992 a 1
FLUOMETURON Aug 1989 a 1
FLUTOLANIL Nov 2001 a 1.3
FLUROXYPYR May 1986 a, c 1
FORCHLORFENURON Feb 2005 a 1.6
FULLERS EARTH Nov 1974 a 7.1
FUNGAL PROTEASE derived from
GERANIUM OIL Feb 2000 a 7.1
GIBBERELLIC ACID Nov 1974 a 1.6
-GLUCANASE derived from Aspergillus niger Feb 2005 a 2.4
HEXAFLURON Nov 1988 a 1
HEXYL ACETATE - a 7.7
HEXYTHIAZOX Feb 1988 a 1
HUMAN OSTEOGENIC PROTEIN-1 (OP-1) Aug 2001 b 6.2
HYDROPRENE Feb 1988 a 1
HYDROXYPROPYL CELLULOSE Nov 1982 a 7.1
ICODEXTRIN Nov 2000 b 6
INDOLE-3-ACETIC ACID Feb 1985 b 1.6
ISOPRENE ALCOHOL - a 7.1
IPRODIONE Feb 1997 a 1
ISOSTEARYL ALCOHOL ETHOXYLATE Nov 1999 a 5.1
KAOLIN Nov 1974 a 7.1
KRESOXIM-METHYL Aug 1999 a 1
KUNZEA OIL Feb 2000 a 7.1
LAURIC ACID Oct 2005 a 7.1
LAURYL ALCOHOL (1-DODECANOL) Nov 1974 a 7.1
LAVANDIN OIL Feb 2000 a 7.1
LAVENDER OIL Feb 2000 a 7.1
LEAD METALLIC - a 7.1
LEMONGRASS OIL Feb 2000 a 7.1
LEPIDOPTEROUS SEX PHEROMONES Nov 1990 a 1
LIMONENE (DIPENTENE) Jun 2002 a 7.1
LINOLEIC ACID Oct 2005 a 7.1
LINSEED FATTY ACIDS Aug 1990 a 2.1
LINURON Feb 1990 a 1
LIQUORICE, DEGLYCYRRHISINISED May 1999 a 7.1
MALEIC HYDRAZIDE Nov 1992 a 1
MANGANESE DIOXIDE May 1999 b 1
MESOLSULFURON-METHYL Feb 2002 a 1.1
METARHIZIUM ANISOPLIAE Feb 2000 b 4.2
METARHIZIUM ANISOPLIAE Jun 2003 a 1.10
METHOPRENE Aug 1987 a 1
METHOXYFENOZIDE Nov 2000 a 1
METHYL ACETATE - a 7.7
METHYL BENZOQUATE Nov 1974 d 2.3
1-METHYLCYCLOPROPENE Jun 2003 a 1.6
METHYL p-HYDROXYBENZOATE Nov 1974 a 7.9
METSULFURONMETHYL Nov 1985 a 1.1
MYRISTIC ACID Oct 2005 a 7.1
NAPROPAMIDE Aug 1987 a 1
NAPTHYL ACETAMIDE Nov 1974 a 1.6
NEROLI OIL Feb 2000 a 7.1
NICARBAZIN Jun 1969 d 2.3
NISIN Jun 2003 a 3.2
NORFLURAZON Nov 1983 a 1.1
NOVALURON Nov 2000 a 1
Nuclear Polyhedrosis Virus
of Helicoverpa armigera
occlusion bodies Feb 2004 a 1.2
OCTYL ALCOHOLS Nov 1974 a 7.1
OLEIC ACID Oct 2005 a 7.1
ORANGE OIL, SWEET Aug 2000 a 7.1
OXABETRINIL Feb 1987 a 1
OXYFLUORFEN May 2001 a 1
PALMAROSA OIL Feb 2000 a 7.1
PALMITIC ACID Oct 2005 a 7.1
PATCHOULI OIL Feb 2000 a 7.1
PECTINASE derived from Aspergillus niger Feb 2005 a 2.4
PENCYCURON Aug 1994 a 1
PENTADECANOIC ACID Oct 2005 a 7.1
PEPPERMINT OIL Feb 2000 a 7.1
PHENMEDIPHAM May 1989 a 1.1
d-PHENOTHRIN Feb 1982 a 7.5, 1.2
PHYTASE Feb 1996 a 2.4
PICLORAM Aug 1987 a 1
PICOLINAFEN May 2000 a 1
PIMELIC ACID Oct 2005 a 7.1
PIPERONYL BUTOXIDE Aug 1991 a 7.5
POLOXALENE Nov 1974 a 7.1
POLY DIALLYL DIMETHYL AMMONIUM
CHLORIDE (PolyDADMAC) Nov 1997 a 4.1
POLYHEDROSIS VIRUS OF HELICO ZEA
OCCLUSION BODIES Nov 1996 a 1
POLY (GNRF) OVALBUMIN Feb 1990 a 2
POLYSORBATE 20 May 2001 a 1
PORCINE SOMATOTROPHIN Nov 1991 c 2
potassium sorbate Oct 2004 a 1.3
POTASSIUM BICARBONATE Jun 2004 a 1
PRAZIQUANTEL Oct 2005 a 2.1
PROPYL ACETATES - a 7.1
PROPYLENE GLYCOL Nov 1974 a 7.1
2-PROPYLENE GLYCOL 1-MONOMETHYL
ETHER Nov 1987 a 4
PROTHIOCONAZOLE June 2005 a 1.3.1
PSEUDOMONAS FLUORESCENS May 1985 a 1.8
PYRIMETHANIL Feb 1996 a 1
PYRIPROXYFEN Aug 1994 a 1
QUASSIA Nov 1974 d 6, 2.1
QUINOXYFEN Nov 2001 a 1.3
ROSEMARY OIL Feb 2000 a 7.1
SAGE OIL (Spanish) Feb 2000 a 7.1
SANDALWOOD OIL Feb 2000 a 7.1
SEAWEED & UNFRACTIONED SEAWEED
EXTRACTS Feb 1985 d 1.5
SIMAZINE Nov 1987 a 1.1
SODIUM BICARBONATE Jun 2004 a 1
sodium propionate Oct 2004 a 1.3
STERIC ACID Oct 2005 a 7.1
SUCRALFATE Aug 1982 a 6.8
SULESOMAB Jun 2002 b 6.1
SULFOSULFURON Feb 1998 a 1
SULPHATED POLYSACCHARIDES - a 7.1
TANNIC ACID Dec 1965 a 7.1
TANNIC ACID/BENZYL ALCOHOL
PRODUCT Nov 1993 a 7.1
TERBACIL Aug 1987 a 1
THAUMATIN Nov 1990 a 3.2
THIDIAZURON Nov 1989 a 1
TRIASULFURON Feb 1988 a 1
TRICHODERMA HARZIANUM May 1996 a 1
(Z)-9-TRICOSENE Aug 1991 a 1
TRIETHYLENE GLYCOL Nov 1974 a 7.1
TRIFLOXYSULFURON Feb 2002 a 1.1
TRIFLURALIN Aug 1990 a 1
TRIFORINE Aug 1987 a 1
Ulocladium oudemansii Oct 2003 a 1.10
UREA Nov 1974 a 7.1
13C-UREA May 2001 a 6.1
VETIVER OIL Feb 2000 a 7.1
VINYL ETHER Nov 1987 b 6
VITAMIN K Jul 1963 a 6.9, 2.8
XANTHOPHYLL (lutein) Nov 1974 a 7.1
XYLANASE derived from
YLANG YLANG OIL Feb 2000 a 7.1
ZINC NAPHTHENATE - a 1.3
APPENDIX C
SUBSTANCES, OTHER THAN THOSE INCLUDED
IN SCHEDULE 9, OF SUCH DANGER TO HEALTH
AS TO WARRANT PROHIBITION OF
SALE, SUPPLY AND USE
ABRUS PRECATORIUS (Jequirity) seed or root for therapeutic use.
ACORUS CALAMUS (calamus) for human therapeutic use.
ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination for domestic use:
(a) in liquid or semi-solid food additive preparations, the pH of which is more than 11.5;
(b) in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous solution or mixture is more than 12.5; or
(b) in liquid or semi-solid automatic dishwashing preparations the pH of which is more than 12.5.
ALLYLISOPROPYLACETYLUREA for therapeutic use.
AMINOPHENAZONE (amidopyrine) and its derivatives for human therapeutic use.
AMYGDALIN for therapeutic use.
ANCHUSA OFFICINALIS for therapeutic use.
ARISTOLOCHIA spp. for therapeutic use.
ARISTOLOCHIC ACID(S) for human therapeutic use.
ASARUM spp. containing aristolochic acid(s) for human therapeutic use.
AZADIRACHTA INDICA (neem) including its extracts and derivatives, in preparations for human internal use except ‘debitterised neem seed oil’.
BASIC ORANGE 31 (2-[(4-aminophenyl)azo]-1,3-dimethyl-1H-imidazolium chloride) in preparations for skin colouration and dyeing of eyelashes or eyebrows.
BITHIONOL for human therapeutic use.
BORAGO OFFICINALIS (Borage) for therapeutic use except the fixed oil derived from the seeds of Borago officinalis.
BRAGANTIA spp. containing aristolochic acid(s) for human therapeutic use.
BUCLOSAMIDE for therapeutic use.
BUNIODYL SODIUM for therapeutic use.
1,4-BUTANEDIOL (excluding its derivatives) in non-polymerised form in preparations for domestic use.
CACALIA spp. for therapeutic use.
CINCHOPHEN and its derivatives for therapeutic use.
CLIOQUINOL and other halogenated derivatives of 8-hydroxyquinoline for human internal use except when being used solely for experimental purposes in humans and such use:
(a) is in accordance with an approval granted under paragraph 19(1)(b), and the requirements of subsection 19(4A), of the Therapeutic Goods Act 1989 (as amended from time to time) - otherwise known as the Clinical Trial Exemption (CTX) scheme; or
(b) is in accordance with the requirements of subsection 18(1) of the Therapeutic Goods Act 1989 and Regulation 12(1A) of the Therapeutic Goods Regulations 1990 (as amended from time to time) - otherwise known as the Clinical Trial Notification (CTN) scheme.
COAL TAR for cosmetic use other than in therapeutic goods.
CONIUM MACULATUM (coniine) for therapeutic use.
COTARNINE for therapeutic use.
CROTALARIA spp. for therapeutic use.
CROTON TIGLIUM for therapeutic use.
CYNOGLOSSUM spp. for therapeutic use.
DICOPHANE (DDT) for therapeutic use.
DIETHYLENE GLYCOL for use in toothpastes or mouthwashes except in preparations containing 0.25 per cent or less of diethylene glycol.
DIETHYLPHTHALATE in sunscreens or personal insect repellents for human use except in preparations containing 0.5 per cent or less of diethylphthalate.
5,6-DIHYDROXYINDOLINE for cosmetic use in preparations containing more than 2 per cent of 5,6-dihydroxyindoline.
DIMETHYLPHTHALATE in sunscreens or personal insect repellents for human use except in preparations containing 0.5 per cent or less of dimethylphthalate.
DULCIN for therapeutic use.
ETHYLENE GLYCOL for use in toothpastes or mouthwashes except in preparations containing 0.25 per cent or less of ethylene glycol.
ETHYLHEXANEDIOL for human use.
EUPATORIUM CANNABINUM (Hemp Agrimony) for therapeutic use.
FARFUGIUM JAPONICUM for therapeutic use.
FORMALDEHYDE (excluding its derivatives):
(a) in oral hygiene preparations containing more than 0.1 per cent of free formaldehyde;
(b) in aerosol sprays for cosmetic use containing 0.005 per cent or more of free formaldehyde;
(c) in nail hardener cosmetic preparations containing 5 per cent or more of free formaldehyde; or
(d) in all other cosmetic preparations containing 0.05 per cent or more of free formaldehyde except in preparations containing 0.2 per cent or less of free formaldehyde when labelled with the warning statement:
HELIOTROPIUM spp. for therapeutic use.
JUNIPERUS SABINE [savin(e)] for therapeutic use.
LEAD COMPOUNDS in paints, tinters, inks or ink additives except in preparations containing 0.1 per cent or less of lead calculated on the non-volatile content of the paint, tinter, ink or ink additive.
LIGULARIA DENTATA for therapeutic use.
MELIA AZEDARACH including its extracts and derivatives.
METHYLDIBROMO GLUTARONITRILE in preparations intended to be in contact with the skin, including cosmetic use.
METHYL METHACRYLATE for cosmetic use except in preparations containing 1 per cent or less of methyl methacrylate as residual monomer in a polymer.
OXYPHENISATIN for therapeutic use.
PARAFORMALDEHYDE (excluding its derivatives):
(a) in oral hygiene preparations containing more than 0.1 per cent of free formaldehyde;
(b) in aerosol sprays for cosmetic use containing 0.005 per cent or more of free formaldehyde;
(c) in nail hardener cosmetic preparations containing 5 per cent or more of free formaldehyde; or
(d) in all other cosmetic preparations containing 0.05 per cent or more of free formaldehyde except in preparations containing 0.2 per cent or less of free formaldehyde when labelled with the warning statement:
PETASITES spp. for therapeutic use.
PHENYLENEDIAMINES in preparations for skin colouration and dyeing of eyelashes or eyebrows except when included in Schedule 6.
POTASSIUM HYDROXIDE (exlcuding its salts and derivatives), in liquid or semi-sold food additive preparations, for domestic use, the pH of which is more than 11.5.
PTERIDIUM spp. for therapeutic use.
PULMONARIA spp. for therapeutic use.
SAFROLE for internal therapeutic use except in preparations containing 0.1 per cent or less of safrole.
SENECIO spp. for therapeutic use.
SILICONES for injection or implantation except when included in Schedule 4.
SODIUM HYDROXIDE (excluding its salts and derivatives), in liquid or semi-sold food additive preparations, for domestic use, the pH of which is more than 11.5.
SYMPHYTUM spp. (Comfrey) for therapeutic or cosmetic use except when included in Schedule 5.
TOLUENEDIAMINE in preparations for skin colouration and dyeing of eyelashes or eyebrows except when included in Schedule 6.
1,1,1-TRICHLOROETHANE in pressurised spray packs for therapeutic use.
TRICHODESMA AFRICANA for therapeutic use.
TRIPARANOL for therapeutic use.
TUSSILAGO FARFARA for therapeutic use.
APPENDIX D
ADDITIONAL CONTROLS ON POSSESSION OR SUPPLY
OF POISONS INCLUDED IN SCHEDULE 4 OR 8
(Note: The following controls apply for the substances shown only when included in Schedule 4 or Schedule 8.)
Poisons available only from or on the prescription or order of an authorised medical practitioner.
CLOMIPHENE for human use.
CLOZAPINE for human use.
CORIFOLLITROPIN ALFA (recombinant follicle stimulant) for human use.
CYCLOFENIL for human use.
DINOPROST for human use.
DINOPROSTONE for human use.
FOLLITROPIN ALPHA (recombinant human follicle-stimulating hormone) for human use.
FOLLITROPIN BETA (recombinant human follicle-stimulating hormone) for human use.
LUTEINISING HORMONE for human use.
TERIPARATIDE for human use.
UROFOLLITROPIN (human follicle-stimulating hormone) for human use.
Poisons available only from or on the prescription or order of a specialist physician or a dermatologist and for which the prescriber must, where the patient is a woman of child-bearing age:
(1) ensure that the possibility of pregnancy has been excluded prior to commencement of treatment; and
(2) if the drug is -
(a) acitretin or etretinate, advise the patient to avoid becoming pregnant during or for a period of 24 months after completion of treatment; or
(b) bexarotene, isotretinoin or thalidomide, advise the patient to avoid becoming pregnant during or for a period of 1 month after completion of treatment.
ACITRETIN for human use.
BEXAROTENE for human use.
ETRETINATE for human use.
ISOTRETINOIN for human oral use.
THALIDOMIDE for human use.
Poisons available only from or on the prescription or order of a medical practitioner authorised or approved by the Secretary of the Commonwealth Department of Health and Ageing under section 19 of the Therapeutic Goods Act 1989.
DRONABINOL (delta-9-tetrahydrocannabinol).
NABIXIMOLS.
Poisons available only from or on the order of a specialist physician and for which the prescriber must, where the patient is a woman of child bearing age:
(a) ensure that the possibility of pregnancy has been excluded prior to commencement of treatment; and
(b) advise the patient to avoid becoming pregnant during or for a period of 1 month after completion of treatment.
APPENDIX D – continued
TRETINOIN for human oral use.
LENALIDOMIDE.
Poisons for which possession without authority is illegal (e.g. possession other than in accordance with a legal prescription).
ANABOLIC STEROIDAL AGENTS, including those separately specified in Schedule 4.
ANDROGENIC STEROIDAL AGENTS, including those separately specified in Schedule 4.
DARBEPOETIN.
DEXTROPROPOXYPHENE.
EPHEDRINE.
EPOETINS.
ERYTHROPOIETIN.
ERYTHROPOIETINS except when separately specified in this Appendix.
GLUTETHIMIDE.
INSULIN-LIKE GROWTH FACTORS.
PHENTERMINE.
SOMATROPIN (human growth hormone).
Poisons available only from or on the prescription or order of a specialist physician and for which the prescriber must, where the patient is a woman of child-bearing age:
(a) ensure that the possibility of pregnancy has been excluded prior to commencement of treatment; and
(b) advise the patient to avoid becoming pregnant during and for a period of 3 months after completion of treatment.
AMBRISENTAN for human use.
BOSENTAN for human use.
SITAXENTAN for human use.
Poisons available only from or on the prescription or order of a dermatologist.
ALEFACEPT for human use.
APPENDIX E
FIRST AID INSTRUCTIONS FOR POISONS
[other than agricultural and veterinary chemicals (including pesticides) registered by
the Australian Pesticides and Veterinary Medicines Authority and
medicines for human use when compliant with the requirements of the
Required Advisory Statements for Medicine Labels]
Directions for First Aid Attention
Under poisons legislation, scheduled substances and their preparations are required to be labelled with appropriate directions for first aid attention in case of poisoning. It is the responsibility of the manufacturer, packer and supplier of a drug or poison to ensure that the first aid instructions included on the label of a poison are appropriate for a specific product. The following code has been prepared as a guide for health authorities and manufacturers in drafting suitable first aid directions for this purpose. Standard statements specified in this appendix may be varied provided that the intent is not changed.
The directions listed for any particular substance may require modification to take into account combination of that substance with other substances, both toxic and non toxic, in a formulation, as well as the physical form and presentation of the product. Any such modification should be concise and readily understood.
These First Aid Instructions include action to be taken in case of eye contamination from substances recognised as causing direct poisoning via the eye, causing severe eye damage or requiring prolonged flushing to free the absorbed substance from the eye tissue. However, it is recognised that many other substances or preparations will require a statement of varying nature depending on the detailed formulation. While the necessity to flush the eyes in case of accident will be so self-evident as not to justify label space in many instances, a statement such as “If in eyes rinse well with water” may be appropriate.
Modified First Aid Instruction on Primary Pack
Where a primary pack contains two or more immediate containers of poisons each requiring different first aid instructions:
(a) each immediate container must be labelled with first aid instructions appropriate for its contents; and
(b) the primary pack must be labelled with the statement:
FIRST AID: See inner packs.
Exempt Preparations
This Appendix applies only to scheduled poisons. The directions are for substances and their preparations at the concentrations at which the schedules apply. If it is thought desirable to show first aid instructions for a substance exempted from the schedules, it is the responsibility of the manufacturer to ensure they are appropriate.
Poisons Information Centre Telephone Numbers
Companies should use the Poisons Information Centre telephone number(s) (Australia 131 126; New Zealand 0800 764 766) appropriate to the country(ies) of sale for the product.
Companies wishing to use a poisons information centre telephone number other than the national telephone numbers for Australia and New Zealand must meet the following criteria:
The poisons information service whose number is used must be attended by adequately trained staff for 24 hour emergency poisons information; and
APPENDIX E – continued
Calls must be logged and submitted for incorporation into the official collection of poisoning data.
STANDARD STATEMENTS
To be grouped together and prefaced with the words “FIRST AID”
(see Sub-paragraph 7(p) of this Standard).
Basic
A For advice, contact a Poisons Information Centre (e.g. phone Australia
131 126; New Zealand 0800 764 766) or a doctor (at once).
Z First aid is not generally required. If in doubt, contact a Poisons Information Centre (e.g. phone Australia 131 126; New Zealand 0800 764 766) or a doctor.
General
G1 Urgent hospital treatment is likely to be needed.
(Note - the words ‘at once’ to be added to instruction A).
G2 If swallowed, give activated charcoal if instructed.
(Note - the words ‘at once’ to be added to instruction A).
G3 If swallowed, do NOT induce vomiting.
G4 Immediately give a glass of water.
G5 Avoid giving milk or oils.
G6 If sprayed in mouth, rinse mouth with water.
Eyes
E1 If in eyes wash out immediately with water.
E2 If in eyes, hold eyelids apart and flush the eye continuously with running water. Continue flushing until advised to stop by a Poisons Information Centre (e.g. phone Australia 131 126; New Zealand 0800 764 766) or a doctor, or for at least 15 minutes.
Respiratory system
R1 If inhaled, remove from contaminated area. Apply artificial respiration if not breathing.
R2 If swallowed or inhaled, remove from contaminated area. Apply artificial respiration if not breathing. Do not give direct mouth-to-mouth resuscitation. To protect rescuer, use air-viva, oxy-viva or one-way mask. Resuscitate in a well-ventilated area.
APPENDIX E, Part 1 – continued
Skin
S1 If skin or hair contact occurs, remove contaminated clothing and flush skin and hair with running water.
S2 If skin or hair contact occurs, remove contaminated clothing and flush skin and hair with running water. Continue flushing with water until advised to stop by a Poisons Information Centre (e.g. phone Australia 131 126; New Zealand 0800 764 766) or a doctor.
S3 If on skin, remove any contaminated clothing, wash skin thoroughly with soap and water, then methylated spirit if available. Contact a Poisons Information Centre (e.g. phone Australia 131 126; New Zealand 0800 764 766) or a doctor.
S4 If on skin, immediately remove any contaminated clothing, wash skin with methylated spirit or PEG (polyethylene glycol) 300 or 400 if available, then flush under running water until advised to stop by a Poisons Information Centre (e.g. phone Australia 131 126; New Zealand 0800 764 766) or a doctor.
S5 If skin contact occurs, immediately remove contaminated clothing. Flush skin under running water for 15 minutes. Then apply calcium gluconate gel. Contact a Poisons Information Centre (e.g. phone Australia 131 126; New Zealand 0800 764 766).
Special Purpose
SP1 If swallowed, splashed on skin or in eyes, or inhaled, contact a Poisons Information Centre (e.g. phone Australia 131 126; New Zealand 0800 764 766) or a doctor at once. Remove any contaminated clothing and wash skin thoroughly. If swallowed, activated charcoal may be advised. Give atropine if instructed.
This page is intentionally blank.
APPENDIX E–continued
FIRST AID INSTRUCTIONS
Standard statements in this Appendix apply to poisons other than agricultural and veterinary chemicals (including pesticides) registered by the Australian Pesticides and Veterinary Medicines Authority. Labelling is not required at concentrations below scheduled levels (see the INTRODUCTION to this Appendix).
Acetic acid A,G3,E2,S1
Acetic anhydride A,G3,E2,S1
Acetone A,G3
Acrolein A,G1,G2,G3,E2,R2,S2
Alkaline salts A,G3,E2,S1
Amines for use as curing agents for epoxy resins A,G3,E1,S1
4-Aminopyridine A,G1,G2,E1,S1
Ammonia
• 5 per cent or less A
• above 5 per cent A,G3,E1,R1,S1
Ammonium persulfate A,G3,E2
Ammonium thiocyanate A
Anhydrides, organic acid, for use as
curing agents for epoxy resins A,G3,E1,S1
Aniline A,E2,R1,S1
Anise oil A,G3
Antimony chloride A,E2,S2
Antimony compounds, except antimony chloride A
Azadirachta indica (neem) including its extracts
and derivatives when included in Schedule 6. A,E1
Barium salts, except barium sulfate A
Basil oil A,G3
Bay oil A,G3
Benzalkonium chloride
• when included in Schedule 5 A,G3,E2
Benzene A,G3,E1,R1,S1
Benzoyl peroxide
• above 20 per cent A,E2,S1
• above 10 per cent up to 20 per cent A,E1
• 10 per cent or less A
Bergamot oil A,G3
Bifluorides
(including ammonium, potassium and sodium salts)
Borax A
Boric acid A
Boron trifluoride
Bromoform A,G3,E2,R1,S2
Brucine A,G1,G2,G3,R2
2-Butoxyethanol and its acetates A,E2,S1
Cadmium compounds A
Cajuput oil A,G3
Camphor A,G1,G3,G5
Carbamide peroxide
• more than 9 per cent up to 60 per cent A,G3,E2,S1
• more than 60 per cent A,G1,G3,G4,E2,S1
Carbon disulfide A,G3,E2,R1,S2
Carbon tetrachloride A,G3,E1,R1,S1
Cassia oil A,G3
Chlorinating compounds, except when
separately specified, containing
• above 4 per cent and below 10 per cent
of available chlorine A,G3,E1,S1
• 10 per cent or more of available chlorine A,G3,E2,S1
WARNING STATEMENTS AND GENERAL SAFETY DIRECTIONS FOR POISONS
[other than agricultural and veterinary chemicals (including pesticides) registered by
the Australian Pesticides and Veterinary Medicines Authority and
medicines for human use when compliant with the requirements of the
Required Advisory Statements for Medicine Labels]
Warning Statements and Safety Directions
It is the responsibility of the manufacturer, packer and supplier of a drug or poison to ensure that the purchaser or user of a product is given sufficient information to be able to use it correctly and safely.
Under poisons legislation, scheduled substances, which may be harmful to the user, must be labelled with appropriate warning statements and/or safety directions. The selection of warning statements and safety directions will depend on the formulation of the product, and the use for which it is sold or supplied. The following code has been prepared as a guide for this purpose.
The wording of warning statements and safety directions specified in this appendix may be varied provided that the intent is not changed. Additional statements also may be added to ensure that the user of a product is sufficiently advised of its harmful nature and how to avoid any deleterious effects.
Poisons Information Centre Telephone Numbers
Companies should use the Poisons Information Centre telephone number(s) (Australia 131 126; New Zealand 0800 764 766) appropriate to the country(ies) of sale for the product.
Companies wishing to use a poisons information centre telephone number other than the national telephone numbers for Australia and New Zealand in warning statement No. 99 in Part 1 of this Appendix must meet the following criteria:
The poisons information service whose number is used must be attended by adequately trained staff for 24 hour emergency poisons information; and
Calls must be logged and submitted for incorporation into the official collection of poisoning data.
WARNING STATEMENTS
Highly corrosive.
Corrosive.
Corrosive liquid.
Strongly alkaline.
Irritant.
May cause cancer.
WARNING - Causes birth defects.
WARNING - May be fatal to children.
Can be fatal to children if sucked or swallowed.
May produce severe burns.
WARNING - Vapour may be harmful.
Vapour is harmful to health on prolonged exposure.
May be fatal if inhaled, swallowed or absorbed through skin.
Dust will irritate and burn eyes, nose and skin.
Liquid will cause burns.
Forms dangerous gas near radiators or naked flames.
Contact with eyes even for short periods can cause blindness.
Product will irritate the eyes, nose, throat and skin.
WARNING - Skin contact may be dangerous. Take every precaution to avoid contact - wash off after spillage and after use.
May give off dangerous gas if mixed with other products.
WARNING - This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.
Highly reactive oxidising chlorine compound.
May cause fire or explosion.
For external washing only. Rinse skin thoroughly after use.
Do not use on broken skin. Wash hands thoroughly after use.
(Powder) (and) (concentrated solutions) are dangerous if swallowed.
Not for therapeutic use.
(Over) (Repeated) exposure may cause sensitisation.
If congestion persists, consult your doctor or pharmacist.
WARNING - Do not use on face or on anal or genital areas.
WARNING - Do not use on face or on anal or genital areas except on doctor’s advice.
This preparation should be part of an overall treatment plan regularly assessed with your doctor.
Do not take for periods longer than four weeks except on medical advice.
WARNING - This medication may be dangerous when used in large amounts or for a long time (period).
CAUTION - This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. Prolonged use without medical supervision could be harmful.
or
CAUTION - This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. Prolonged or excessive use without medical supervision could be harmful.
For use under medical supervision only.
Consult a doctor before giving this medication to children or teenagers with chicken pox, influenza or fever.
CAUTION - Do not use for children under 2 years old unless a doctor has told you to.
This medication may cause drowsiness. If affected do not drive a vehicle or operate machinery. Avoid alcohol.
This medication may cause drowsiness and may increase the effects of alcohol. If affected do not drive a motor vehicle or operate machinery.
Do not give to children under 12 years of age. Do not use beyond 48 hours or in pregnancy or lactation except on doctor’s advice.
WARNING - Overuse may stain the skin or mouth.
Use of this product is not necessary in areas supplied with fluoridated water.
WARNING - May be dangerous, particularly to children, if you use large amounts on the skin, clothes or bedding or on large areas of the body, especially if you keep using it for a long time.
WARNING - If a pigmented spot or mole has recently become darker, changed colour, become enlarged or itchy, or bleeds, do not use this product, see your doctor immediately. Do not use on children. Do not use near the eyes. Mild irritation may occur; stop use if it becomes severe. If fading is not evident in three months, seek doctor’s advice.
WARNING - Contains (name of substance) which causes birth defects in laboratory animals. Women of child bearing age should avoid contact with (name of substance).
WARNING - This product contains (name of substance) which causes birth defects in certain laboratory animals. Women of child bearing age are advised not to mix, load or spray this product. They should keep out of crops being sprayed.
WARNING - This product forms cyhexatin which causes birth defects in certain laboratory animals. Women of child bearing age are advised not to mix, load or spray this product. They should keep out of crops being sprayed.
WARNING - Do not mix with other medication except on veterinarian’s advice.
Unless adequately fired, utensils glazed with this preparation must not be used as containers for food or beverages; to do so may cause lead poisoning.
51. Irritant to skin, eyes, mucous membranes and upper respiratory tract.
Breathing vapour or spray mist is harmful and may cause an asthma-like reaction.
CAUTION - (Name of substance) should not be used by pregnant women.
54. Seek medical advice before first course of treatment.
55 Keep from eyes, lips, mouth and sensitive areas of the neck. If excessive swelling, irritation, redness or peeling occurs, discontinue use. If these persist, consult a physician. Avoid excessive exposure to sunlight and other sources of ultra violet light.
WARNING - Can cause elevated blood pressure and interact adversely with other medication.
Not to be applied to infants under 12 months of age unless on doctor’s advice.
Highly reactive oxidising bromine and chlorine compound.
May cause allergy.
Do not mix with detergents or other chemicals.
WARNING - Can react with other medicines. Ask your doctor or pharmacist before taking.
Do not use if pregnant.
See a doctor if you are pregnant or diabetic.
See a doctor (or) (dentist) if no better after (Insert number of days as per approved Product Information) days.
If getting better, keep using for (Insert number of days as per approved Product Information ) days.
See a doctor if problem returns.
Do not use if pregnant or likely to become pregnant.
If symptoms persist beyond 5 days consult a doctor (or) (dentist).
If symptoms recur within two weeks of completing the course, consult a doctor.
Use only under medical supervision if you are taking other medicines.
Do not use during the last three months of pregnancy.
Do not use in the eyes.
Do not use for acne.
Do not use under waterproof bandages unless a doctor has told you to.
Do not use for more than 7 days unless a doctor has told you to.
Do not become pregnant during use or within (Insert number of months as per approved Product Information) month(s) of stopping treatment.
WARNING - May cause birth defects.
Attacks skin and eyes.
Will irritate eyes.
(Intentionally blank)
(Intentionally blank)
(Intentionally blank)
This paint is dangerous to health, even when dry.
For industrial use only.
Do not use on toys or furniture.
Do not use on, in or around the home.
Breathing the vapour is dangerous.
Provide adequate ventilation during application.
Do not use in the presence of a naked flame.
Do not smoke.
This paint contains lead and is dangerous to health, even when dry.
For industrial use only.
Do not use on toys or furniture.
Do not use for painting any building or fixed structure.
Do not use where contact with food or drinking water is possible.
This tinter contains lead.
Do not add to any paint which is for application to any toy, furniture, building (interior or exterior), fixed structure or to anything which may contact food or drinking water.
(Insert brand name) remains in the body for many months after treatment has stopped. Do not become pregnant or father a child before consulting your doctor.
This product is not recommended for dyeing eyelashes or eyebrows. To do so may be injurious to the eye.
Application to skin may increase sensitivity to sunlight.
This preparation is to aid sleep. Drowsiness may continue the following day. If affected do not drive or operate machinery. Avoid alcohol.
CAUTION - Total iodine intake may exceed recommended level when taking this preparation.
WARNING - Contains iodine - do not take when pregnant except on physician’s advice.
Causes severe burns, which are not likely to be immediately painful or visible.
WARNING - Contains nitrite. Substitution for table or cooking salt may be dangerous, particularly for young children.
CAUTION - Do not use for children under 12 years old unless a doctor has told you to.
CAUTION - This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. If symptoms persist or recur within two weeks, consult a doctor.
Adults: Keep to the recommended dose. Don’t take this medicine for longer than a few days at a time unless advised to by a doctor.
Children and adolescents: Keep to the recommended dose. Do not give this medicine for longer than 48 hours at a time unless advised to by a doctor.
If an overdose is taken or suspected, ring the Poisons Information Centre (Australia 131 126; New Zealand 0800 764 766) or go to a hospital straight away even if you feel well because of the risk of delayed, serious liver damage.
Do not take with other products containing paracetamol, unless advised to do so by a doctor or pharmacist.
Don’t use [this product / name of the product]:
If you have a stomach ulcer
In the last 3 months of pregnancy [This statement may be omitted in preparations used exclusively for the treatment of dysmenorrhoea.]
If you are allergic to (name of substance) or anti-inflammatory medicines.
Unless a doctor has told you to, don’t use [this product / name of the product]:
For more than a few days at a time
With other medicines containing aspirin or other anti-inflammatory medicines
If you have asthma
In children under 12 years of age
In children 12-16 years of age with or recovering from chicken pox, influenze or fever
If you are pregnant.
See a doctor before taking [this product / name of the product] for thinning the blood or for your heart. [This statement may be omitted in products for inhibition of platelet aggregation or with additional active ingredients.]
Unless a doctor has told you to, don’t use [this product / name of the product]:
For more than a few days at a time
With other medicines containing (name of substance) or other anti-inflammatory medicines
If you have asthma
If you are pregnant [This statement may be omitted in preparations used exclusively for the treatment of dysmenorrhoea].
Do not use on the bedding or clothing of infants or in the bedrooms of children 3 years of age or less.
Contains formaldehyde.
SAFETY DIRECTIONS - GENERAL
To be grouped together and prefaced with the words “SAFETY DIRECTIONS” - see Sub-paragraph 7(n) to this Standard.
Avoid contact with eyes.
Attacks eyes - protect eyes when using.
Wear eye protection when mixing or using.
Avoid contact with skin.
Wear protective gloves when mixing or using.
Wash hands after use.
Wash hands thoroughly after use.
Avoid breathing dust (or) vapour (or) spray mist.
Use only in well ventilated area.
Ensure adequate ventilation when using.
11. No smoking.
Do not allow product to come into contact with other chemicals, especially acids.
Do not allow product to come into contact with combustible materials such as paper, fabric, sawdust or kerosene.
Do not allow to get damp.
Store under cover in a dry, clean, cool, well ventilated place away from sunlight.
Store and transport in an upright container.
Do not mix with other chemicals.
Do not mix with different types of chlorinating chemicals.
Use clean containers for dispensing.
Mix with water only.
Do not add water to product - add product to water, but in case of fire drench with water.
In case of spillage flush with large quantities of water.
Keep away from heat, sparks and naked flames.
Avoid contact of the crystals or strong solutions with the eyes, mouth, nose and other mucous membranes.
APPENDIX F, Part 2–continued
Avoid contact with food.
Avoid contact with clothing.
Wear a positive-pressure air-supplied full-face respirator whilst spraying and until spray mist has been effectively dispersed.
Do not mix with hot water.
Obtain a supply of calcium gluconate gel.
(Intentionally blank.)
Do not use on broken skin.
Do not use under occlusive dressing.
Mix strictly according to instructions.
May cause fire if it comes into contact with other chemicals, paper or other flammable materials.
Wash gloves thoroughly, immediately after use.
Protect cuticles with grease or oil.
PART 3
POISONS (other than agricultural and veterinary chemicals)
TO BE LABELLED WITH WARNING STATEMENTS
OR SAFETY DIRECTIONS
(Where more than one statement or direction is required they may be combined to form simple sentences where appropriate.)
STATEMENTS DIRECTIONS
Acetic acid in concentrations of 80 per cent 2 1,4,8
or more except when in Schedule 2.
Acetic anhydride 2 1,4,8
Acetone in concentrations greater
than 75 per cent. 1,4,8
Acitretin 7,62,76
Adapalene for topical use. 77,62
Alclometasone when included in Schedule 3. 38,72,73,
74,75
Alkaline salts 4 1,4
Ambrisentan 7,62,76
Amines used as curing agents for epoxy resins. 1,3,4,5,8
Ammonia/ammonium hydroxide in concentrations 4 1,4,8
greater than 20 per cent ammonia except
in smelling salts.
Ammonium persulfate 5,21,25 1,5,23,33,34
Anhydrides, organic acid, for use as curing agents 1,3,4,5,8
for epoxy resins.
Aniline 13 1,4,8
Antihistamines not separately specified 39 or 40
in this Appendix except:
(a) dermal, ocular, parenteral and
paediatric preparations;
(b) oral preparations of astemizole,
desloratadine, fexofenadine,
loratadine or terfenadine;
(c) nasal preparations of azelastine;
or
(d) preparations for the treatment
of animals.
Aromatic extract oils 1,3,4,5,6
Aspirin
(a) for inhibition of 36
platelet aggregation.
(b) in sustained release 36
preparations containing
650 mg or more of aspirin.
(c) in other preparations. 101,102,103
Astemizole 61
Azadirachta indica (neem) including its
extracts and derivatives when
included in Schedule 6. 67
Azocyclotin 48
Benomyl 46
Benzene 12 1,4,9
Benzoyl peroxide when included in Schedule 2. 55
Benzoyl peroxide when included in Schedule 5. 1,4,8
Bergamot oil 89
Beryllium 1,4,8
Bexarotene
(a) for human use. 7,62,76
Bifluorides (including ammonium,
potassium and sodium salts)
Bithionol for the treatment of animals. 1,4,8
Boron trifluoride (including mixtures
that generate boron trifluoride)
Bosentan 7,62,76
Bromoform 1,4,8
2-Butoxy-2’-thiocyanodiethyl ether 1,4,8
2-Butoxyethanol and its acetates 1,4,8
Camphor
(a) in block, ball, disc or pellet form, 9
enclosed in a device which, in
normal use, prevents removal or
ingestion of its contents.
(b) in other forms. 9 1
Carbamide peroxide
(a) more than 9 per cent up to 30 per cent. 5 1
(b) more than 30 per cent up to 60 per cent. 5 2
(c) more than 60 per cent. 2 2,4
Carbon disulphide 12 1,4,8,9,23
Carbon tetrachloride 12 1,4,8,9
Cassia oil 4
Chlorinating compounds
(a) in household cleaning or 20
bleaching preparations.
(b) in preparations containing less than 11 1,4,10
10 per cent of available chlorine.
(c) in liquid preparations containing 3,18 1,4,6,8,10,
10 per cent or more of 15,16,17,18,
available chlorine. 19,20,22,26
(d) in dry preparations containing 10,18,22,23 1,4,8,12,13,
10 per cent or more of 14,15,16,17,
available chlorine. 18,19,20,21,
22,26
(e) in dry preparations containing 10,18,22 1,4,8,12,13,
10 per cent or more of available 14,15,16,17,
chlorine certified by a relevant 18,19,20,21,
State or Territory authority as not 22,26
being a Dangerous Good of
Class 5.1 (oxidising substances).
(f) in compressed block or tablets 10,22,23 12,13,14,15,
containing 10 per cent or more of 17,18,19,21
available chlorine except in
preparations for use in toilet cisterns
only, containing 15 g or less of
trichloroisocyanuric acid.
(g) in other compressed blocks or 10,22 12,13,14,15,
tablets containing 10 per cent or 17,18,19,21
more of available chlorine certified
by a relevant State or Territory
authority as not being a Dangerous
Good of Class 5.1 (oxidising
substances), as specified in the
Australian Code for the Transport
of Dangerous Goods by Road and
Rail except in preparations for use
in toilet cisterns only, containing
15 g or less of trichloroisocyanuric acid.
Chloroform when included in Schedule 6 1,4,8
alpha-Chlorohydrin 13,51 1,4,8,9
Chromates (including dichromates) of 1,4,8
alkali metals or ammonia
Chromium trioxide 2,14,15,23 1,4,8,13
Cimetidine when included in Schedule 3 70,96
Cinnamon bark oil 4
Clobetasone when included in Schedule 3. 72,73,74,75,95
Clotrimazole in vaginal preparations 54,63,64,66
Clove oil 1
Cyanides when included in Schedule 7. 13 4,8
Cyanuric acid 1,4,8
Cyclohexanone peroxide 1,4,8
Cysteamine 1
4,4-Diaminodiphenylmethane 1,4,8
(methylene dianiline)
ortho-Dichlorobenzene 1,4,8
para-Dichlorobenzene 1,4
Dichloroethylene 1,4,8
Dichloroethyl ether 1,4,8
Dichloroisocyanurates
(a) in household cleaning or 20
bleaching preparations.
(b) in preparations containing 11 1,4,10
less than 10 per cent of
available chlorine.
(c) in liquid preparations containing 3,18 1,4,6,8,10,
10 per cent or more of available 15,16,17,18,
chlorine. 19,20,22,26
(d) in dry preparations containing 10,18,22,23 1,4,8,12,13,14,
10 per cent or more of available 15,16,17,18,19,
chlorine. 20,21,22,26
(e) in dry preparations containing 10,18,22 1,4,8,12,13,14,
10 per cent or more of available 15,16,17,18,19,
chlorine certified by a relevant 20,21,22,26
State or Territory authority as not
being a Dangerous Good of
Class 5.1 (oxidising substances),
as specified in the Australian Code
for the Transport of Dangerous
Goods by Road and Rail.
(f) in anti-bacterial tablets 60
containing 2.5 g or less of sodium
dichloroisocyanurate.
(g) in other compressed blocks or 10,22,23 12,13,14,15,
tablets containing 10 per cent or 17,18,19,21
more of available chlorine
except in preparations containing 21 g
or less of sodium dichloroisocyanurate
for use in toilet cisterns only.
(h) in other compressed blocks or tablets 10,22 12,13,14,15,17,
containing 10 per cent or more of 18,19,21
available chlorine certified by a
relevant State or Territory authority
as not being a Dangerous Good of
Class 5.1 (oxidising substances), as
specified in the Australian Code for
the Transport of Dangerous Goods
by Road and Rail except in preparations
containing 21 g or less of sodium
dichloroisocyanurate for use in toilet
cisterns only.
(i) in other compressed blocks or
tablets containing 10 per cent
or more of available chlorine
in preparations containing 5 g
or less of sodium
dichloroisocyanurate for use in
toilet bowls only.
(i) during storage 10,22,23 12,13,14,15,17,
18,21
(ii) during use 5 1,4,7,12
(j) in other compressed blocks or tablets
containing 10 per cent or more of available
chlorine certified by a relevant State or
Territory authority as not being a
Dangerous Good of Class 5.1 (oxidising
substances) as specified in the
Australian Code for the Transport of
Dangerous Goods by Road and Rail
in preparations containing 5 g or less of
sodium dichloroisocyanurate for use in
toilet bowls only.
(i) during storage 10,22 12,13,14,15,17,
18,21
(ii) during use 5 1,4,7,12
Dichloromethane (methylene chloride)
(a) in paint or lacquer removers. 12,16 1,4,8,11
(b) other than in paint or lacquer 1,4,8,25
removers.
Diclofenac 101,104
Dienestrol 67
Diethanolamine when included in Schedule 5. 5 1,4
Diethanolamine when included in Schedule 6. 2,11,18 1,4,8
Diethyltoluamide for human use. 44
5,6-Dihydroxyindoline 21,28
Dimethylformamide 1,4,8
Dimethyl sulfate 2 1,4,8
Dimethyl sulfoxide
(a) when not packed and labelled 27 1,4,5,8
for therapeutic use.
(b) when packed and labelled 49 1,4,5,8
for treatment of animals.
Dinitrocresols (and their homologues) 1,4,8
except when for therapeutic use.
Dinitrophenols (and their homologues) 1,4,8
except when for therapeutic use.
Dinocap 47
Dioxane 1,4,8
Diphenoxylate when included in Schedule 3. 39 or 40,41
Econazole in vaginal preparations when 54,63,64,66
included in Schedule 3.
Ephedrine in nasal preparations 29
Epichlorohydrin 2 1,4,8
Epoxy resins, liquid. 1,3,4,5,8
Ethanolamine when included in Schedule 5. 5 1,4
Ethanolamine when included in Schedule 6. 2,11,18 1,4,8
Ether when included in Schedule 5 or 6. 1,4,8
Ethoxyethylmercuric chloride 1,4
Ethyl bromide 1,4,8
Ethylene chlorohydrin 1,4,8
Ethylene glycolmonoalkyl ethers and 1,4,8
their acetates except when
separately specified.
Ethylene oxide 1,4,8
Ethylmercuric chloride 1,4
Ethyl methacrylate 28 4,9,23
Etretinate 7,62,76
Eugenol 1
Famotidine when included in Schedule 2. 96
Fenoterol in metered aerosols. 32
Fluconazole in oral preparations 64
Fluorides (including silicofluorides) 1,4
when included in Schedule 5 or 6
except when separately specified.
Formaldehyde
(a) in nail hardener cosmetics. 106 1,4,8,36
(b) in other preparations. 106 1,4,8
Formic acid 1,4,8
Glazing preparations containing lead compounds. 50
Glutaraldehyde except when in Schedule 2
(a) 25 per cent or less. 5,59 1,4,5
(b) more than 25 per cent. 3,59 1,4,5,8
Glycolic acid 79 1,5,6,31
Hexachlorophane in preparations 24
for skin cleansing purposes
containing 3 per cent or
less of hexachlorophane.
Hydrazine 1,4,8
Hydrochloric acid
(a) 30 per cent or less of HCl. 1,4
(b) more than 30 per cent of HCl. 1,4,8
Hydrocortisone
(a) for dermal use when included 38,72,73,74,75
in Schedule 2 or 3.
(b) for topical rectal use when 38,75
included in Schedule 2 or 3.
Hydrocyanic acid when included in 13 4,8
Schedule 7.
Hydrofluoric acid (including mixtures
that generate hydrofluoric acid)
Hydrogen peroxide
(a) more than 3 per cent up to 10 per cent. 5 1
(b) more than 10 per cent up to 20 per cent. 5 2
(c) more than 20 per cent. 2 2,4
Hydroquinone
(a) when in Schedule 2. 45
(b) except when in Schedule 2 or 4. 1,4
Hydrosilicofluoric acid
(including mixtures that generate
hydrosilicofluoric acid)
8-Hydroxyquinoline (including salts and 33
derivatives) when prepared for
internal use.
Ibuprofen 101,104
Iodine
(a) more than 20 per cent. 1,4,8
(b) in preparations for human 91,92
internal therapeutic use
containing 300 micrograms
or more of iodine per
recommended daily dose.
Ipratropium bromide in metered aerosols. 32
Isocyanates (free organic)
(a) when in paint. 28,52 1,5,8,10,27
(b) other than in paint. 28,52 1,4,8
Isoprenaline in metered aerosols 32
Isotretinoin
(a) for human oral use. 7,62,76
Lead compounds
(a) in hair cosmetics. 25
(b) when in Schedule 6. 1,4,8
Leflunomide 7,62,87
Lemon oil 89
Lenalidomide 7,62,76
Levocabastine
(a) in eye or nasal preparations containing 62
0.5 mg/mL or less of levocabastine.
(b) in other preparations. 62 and
either 39 or 40
Lime oil 89
Loperamide when in Schedule 2. 41
Magnesium chlorate 1,4
Mefenamic acid 101,104
Mercuric thiocyanate 1,4
Metacresolsulphonic acid and formaldehyde 1,4
condensation product for the
treatment of animals.
Methanol except in methylated spirit. 1,4,8
Methoxamine in nasal preparations for 29
topical use.
Methyl chloride 1,4,8
Methylene bisthiocyanate 1,4
Methyldibromo glutaronitrile 28 1,4,7
Methyl ethyl ketone 5 1,4,8
Methyl ethyl ketone peroxide 2 2,3,4,6
Methyleugenol 1,6
Methyl iso-amyl ketone 1,4,8
Methyl iso-butyl ketone 1,4,8
Methyl iso-thiocyanate 5,12 1,4,8
Methyl methacrylate 28 4,9,23
Methylnorbornylpyridine 59
1-(beta-Methyl sulphonamidoethyl)-
2-amino-3-N,N-diethylaminobenzene 1,4,8
Miconazole in vaginal preparations 54,63,64,66
Misoprostol 53
Naphazoline in nasal preparations for 29
topical use.
Naphthalene
(a) in block, ball, disc or pellet form, 9,105
enclosed in a device which, in
normal use, prevents removal or
ingestion of its contents.
(b) in other forms. 9,105 1
Naproxen 101,104
Nicotine except when in tobacco 1,4
or when included in Schedule 2.
Nitric acid
(a) 75 per cent or less HNO3. 2 1,4
(b) more than 75 per cent HNO3. 2 1,4,8
Nitrobenzene 1,4,8
Nitrophenols 1,4
Nitroprussides in aerosols. 84 8
Nizatidine when included in Schedule 2. 96
Noradrenaline in metered aerosols. 32
Nystatin in vaginal preparations 54,63,64,65,66
Orange oil (bitter) 89
Orciprenaline in metered aerosols. 32
Oxalates, metallic 4,8
Oxalic acid 2 4,8
Oxymetazoline in nasal preparations 29
Paint
(a) First Schedule paints. 83
(b) Second Schedule paints. 84
Paracetamol 97 and/or 98,99,100
Pentachlorophenol 1,4,8
Peracetic acid 2 1,4,8
Permanganates 2 24
Phenol and any other homologue of phenol. 1,4
Phenols 5
Phenylenediamines and alkylated
phenylenediamines
(a) in hair dyes. 21
(b) in preparations other than hair dyes. 1,4,8
Phenylephrine in nasal preparations 29
N,N-bis(phenylmethylene)-bicyclo-
(2.2.1)heptane-2,5-dimethanamine 5,28 1,4,5,10
N,N-bis(phenylmethylene)-bicyclo-
(2.2.1)heptane-2,6-dimethanamine 5,28 1,4,5,10
ortho-Phenylphenol except when in 1,4
antiseptics.
Phenylpropanolamine 56
Phenytoin in pastes for the treatment of horses. 9
Phosphonic acid 1,4
Phosphoric acid 1,4
Phosphorus (yellow) 2 1,4
ortho-Phthalaldehyde
(a) when included in Schedule 6. 51,52,59 2,4,5,8,10
(b) when included in Schedule 5. 51,52,59 1,4,5,8,10
(a) in preparations containing 5 1,4,6
0.5 per cent or less of potassium
(b) in solid preparations containing 2,10,78 3,5,28
more than 0.5 per cent of potassium
(c) in liquid preparations containing 2,10,78 3,5
more than 0.5 per cent of potassium
Potassium metabisulphite 5,26 1,4
Potassium nitrite in pickling or curing salts. 94
Potassium persulfate 5,21,25 1,5,23,33,34
Potassium sulfide 2 1,4
Propionic acid when in Schedule 6. 2 1,4
Ranitidine when included in Schedule 2. 96
Safrole
(a) in preparations for
therapeutic use. 1
(b) other than for therapeutic use. 1,4
Salbutamol in metered aerosols or in dry 32
powder formulations.
Salicylamide 34 or 35
Sassafras oil
(a) in preparations for therapeutic use. 1
(b) other than for therapeutic use. 1,4
Selenium compounds except when for 1,4,8
therapeutic use (human or animal).
Silver in smoking deterrents. 42
Sitaxentan 7, 62, 76
Sodium aluminate 2 1,4
Sodium chlorate 1,4
Sodium dodecylbenzene sulfonate 79 1
Sodium fluoride in preparations for 43
human ingestion when in Schedule 2.
Sodium hydrogen sulfate 1,4,8
Sodium hydrosulfite 5,26 1,4,8
(more than 50 per cent)
Sodium hydroxide
(a) in preparations containing 5 1,4,6
0.5 per cent or less of sodium
(b) in solid preparations containing 2,10,78 3,5,28
more than 0.5 per cent of sodium
(c) in liquid preparations containing 2,10,78 3,5
more than 0.5 per cent of sodium
Sodium laureth-6 carboxylate 79 1
Sodium metabisulphite 5,26 1,4
(more than 50 per cent)
Sodium nitrite in pickling or curing salts 94
Sodium persulfate 5,21,25 1,5,23,33,34
Sodium sulfide 2 1,4
Styrene 1,4,8
Sulfamic acid 2 1,4
Sulfuric acid 2 1,4
Symphytum spp. (Comfrey) 31,32
when included in Schedule 5.
Tazarotene for topical use. 77,62
Terbutaline in metered aerosols or in 32
dry powder formulations.
Terfenadine 61
Terpenes, chlorinated 1,4,8
Tetrachloroethane 12 8
Tetrachloroethylene when in Schedule 5 or 6. 12,16 1,4,8,11
Tetrahydrozoline in nasal 29
preparations for topical use.
Thalidomide 7,62,76
Thiourea 1,4
Toluene 1,4,8
Toluenediamine
(a) in hair dyes. 21
(b) in preparations other than hair dyes. 1,4,8
Tramazoline in nasal preparations 29
Tretinoin
(a) for human oral use. 7,62,76
Triamcinolone when in topical preparations 64 or 68
for the treatment of mouth ulcers.
Trichloroacetic acid except when for 2 1,4
therapeutic use.
1,1,1-trichloroethane 8,9
Trichloroethylene except when for 12 1,4,5,8,9
therapeutic use.
Trichlorophenol 1,4,8
Triethanolamine 5 1,4
Triethyl phosphate 1,4,8
Trifluoromethanesulfonic acid
(a) more than 10 per cent. 1,17 1,4,8
(b) 10 per cent or less. 1,4,8
Triisopropanolamine lauryl ether sulfate 1,4,6
3,6,9-Trioxaundecanedioic acid 5 1
Tymazoline in nasal preparations for topical use. 29
Vinclozolin 46
Xylene 1,4,8
Xylometazoline in nasal preparations for topical use. 29
Zinc chloride 1,4
Zinc sulfate when in Schedule 6. 1,4
APPENDIX G
DILUTE PREPARATIONS
The requirements of this Standard do not apply to a poison listed in Column 1 of this Appendix at a concentration not more than that specified in Column 2 in respect of that poison.
Column 1 Column 2
Poison Concentration
(quantity per litre
or kilogram)
ACETYLCHOLINE 1 mg
ALDOSTERONE 10 micrograms
ANTIMONY COMPOUNDS 1 mg
APOMORPHINE 1 mg
ARSENIC 1 mg
ATROPA BELLADONNA (belladonna) 300 micrograms
ATROPINE 300 micrograms
CANTHARIDIN 10 micrograms
CHLORINE 5 mg
CROTON TIGLIUM (croton oil) 1 mg
DIOXANE 100 mg
ERYSIMUM spp. 1 mg
FOLLICLE-STIMULATING HORMONE 100 micrograms
GELSEMIUM SEMPERVIRENS 1 mg
GLUCAGON 100 micrograms
GLYCERYL TRINITRATE 100 micrograms
GROWTH HORMONE 10 micrograms
HALOPERIDOL 1 mg
HYDROCYANIC ACID 1 microgram
HYOSCINE 300 micrograms
HYOSCYAMINE 300 micrograms
HYOSCYAMUS NIGER 300 micrograms
HYPOTHALAMIC RELEASING FACTORS 10 micrograms
INDOMETHACIN 1 mg
MERCURY 1 mg
METHYLMERCURY 300 micrograms
NAPHTHALENE 1 mg
NERIUM OLEANDER 1 mg
OESTRADIOL 10 micrograms
OESTRONE 100 micrograms
OXYTOCIN 1 microgram
PHOSPHORUS 1 mg
PODOPHYLLUM RESIN (podophyllin) 1 mg
PROGESTERONE 1 mg
PROPRANOLOL 1 mg
SELENIUM 100 micrograms
STROPHANTHUS spp. 1 mg
STRYCHNINE 1 mg
TESTOSTERONE 1 mg
THYROXINE 10 micrograms
APPENDIX H
SCHEDULE 3 POISONS PERMITTED TO BE ADVERTISED
Amorolfine.
Azelastine.
Butoconazole.
Clotrimazole.
Diclofenac.
Dimenhydrinate for the prevention and relief of motion sickness.
Diphenoxylate.
Econazole.
Fluconazole.
Hydrocortisone.
Miconazole.
Nystatin.
APPENDIX I
UNIFORM PAINT STANDARD
This Appendix provides regulations for adoption by the States and Territories.
A person must not manufacture, sell, supply or use a First Schedule Paint for application to:
(1) a roof or any surface to be used for the collection or storage of potable water; or
(2) furniture; or
(3) any fence, wall, post, gate or building (interior or exterior) other than a building which is used exclusively for industrial purposes or mining or any oil terminal; or
(4) any premises used for the manufacture, processing, preparation, packing or serving of products intended for human or animal consumption.
A person must not manufacture, sell, supply or use a Third Schedule paint.
A person must not manufacture, sell, supply or use a paint for application to toys unless the paint complies with the specification for coating materials contained in Australian/New Zealand Standard AS/NZS ISO 8124.3:2003 entitled Safety of toys Part 3: Migration of certain elements.
A person must not manufacture, sell, supply, or use a paint containing a pesticide except a fungicide, algicide, bactericide or antifouling agent.
The First Schedule
The proportion of a substance for the purposes of this Schedule is calculated as a percentage of the element present in the non-volatile content of the paint.
ANTIMONY or antimony compounds
other than antimony titanate pigments more than 5 per cent
BARIUM salts except barium sulfate or
barium metaborate more than 5 per cent
CADMIUM or cadmium compounds more than 0.1 per cent
CHROMIUM as chromates of ammonia,
barium, potassium, sodium, strontium or zinc more than 5 per cent
SELENIUM or selenium compounds more than 0.1 per cent
APPENDIX I–continued
The Second Schedule
DICHLOROMETHANE (methylene chloride) more than 5 per cent by wt
ETHYLENE GLYCOL MONOALKYL ETHERS more than 10 per cent by vol
and their acetates
TOLUENE more than 50 per cent by vol
XYLENE more than 50 per cent by vol
The Third Schedule
The proportion of a substance for the purposes of this Schedule is calculated as a percentage of the element present in the non-volatile content of the paint.
LEAD or lead compounds more than 0.1 per cent
APPENDIX J
CONDITIONS FOR AVAILABILITY AND USE OF
SCHEDULE 7 POISONS
CONDITIONS FOR AVAILABILITY AND USE
(NOTE - the following controls are recommended for poisons only when included in Schedule 7. These conditions for availability and use may be implemented through poisons controls or other State or Territory legislation.)
Not to be available except to authorised or licensed persons.
Not to be used in printing inks.
Not to be used except by or in accordance with the directions of accredited government vermin control officers.
Not to be used in industries which handle, process or store foods, animal feeds or packaging materials.
APPENDIX J–continued
A poison listed in this Appendix is to be available only in accordance with the conditions specified beside it in the “Conditions” column. The conditions apply only when the poison is included in Schedule 7.
Abamectin 1
Acibenzolar-s-methyl 1
Acrolein 1
Acrylonitrile 1
Alachlor 1
Allyl alcohol 1
4-Aminopyridine 1
Arprinocid 1
Arsenic 1
Azocyclotin 1
Benzene 1
Bifluorides (including ammonium, potassium and sodium salts) 1
Opium in any form except the alkaloids noscapine and papaverine.
Oxazepam
Oxycodone
Paliperidone
Papaveretum
Pentazocine
Pentobarbitone
Pericyazine
Perphenazine
Pethidine
Phenelzine
Pheniramine
Phenobarbitone
Phenoperidine
Phenyltoloxamine
Pholcodine
Pimozide
Pizotifen
Prazepam
Pregabalin
Prochlorperazine
APPENDIX K – continued
Promazine
Promethazine
Protriptyline
Quetiapine
Quinalbarbitone
Risperidone
Rotigotine
Secbutobarbitone
Temazepam
Thenyldiamine
Thiethylperazine
Thiopropazate
Thioridazine
Thiothixene
Tramadol
Tranylcypromine
Trifluoperazine
Trimeprazine
Trimipramine
Triprolidine
Ziprasidone
Zolpidem
Zonisamide
Zopiclone
APPENDIX L
REQUIREMENTS FOR DISPENSING LABELS FOR HUMAN AND VETERINARY MEDICINES
Part 1
(See Part 2 Sub-paragraph 14(1))
General requirements for dispensing labels
(1) All details, words and other required information on a label on a container of a substance for therapeutic use must be in the English language in letters at least 1.5 millimetres in height.
(2) All symbols, numbers and words on a label must be in durable characters.
(3) The label on a container of a substance for therapeutic use must contain the following details:
(a) the name, address and telephone number of the dispenser supplying the substance;
(b) the approved name of the substance and / or its proprietary name (unless it is a preparation compounded in accordance with the dispenser’s own formula);
(c) adequate directions for use;
(d) the strength and form of the substance;
(e) the total quantity of the goods in the container;
(f) the words “KEEP OUT OF REACH OF CHILDREN” in red on a white background;
(g) if the substance is intended for external use only, the word “POISON”, or the words “FOR EXTERNAL USE ONLY”, in red on a white background;
(h) if the substance is a medicine, the name of the person for whom it was dispensed; and
(i) if the substance is a veterinary chemical, the species of animal, the name of the animal’s owner and the words “FOR ANIMAL TREATMENT ONLY”.
(4) The label on a container of a medicine or veterinary chemical that is supplied on prescription must also include:
(a) the prescription reference number;
(b) the date on which the prescription was supplied (unless that date is clear from the prescription reference number); and
(c) the directions for use set out in the prescription.
Part 2
Additional labelling requirements for certain human medicines
(See Part 2 Sub-paragraph 14(2))
Medicines required to be labelled with certain warning statements
A substance listed in Column 1 of the following table must be labelled with the warning statement in Appendix F, Part 1 as specified opposite in Column 2.
Column 1substanceAcitretin:(i) for oral use.(ii) for topical use.Adapalene:(i) for oral use.(ii) for topical use.Ambrisentan.Bexarotene:(i) for oral use.(ii) for topical use.Bosentan.Dienestrol.Etretinate:(i) for oral use.(ii) for topical use.Isotretinoin:(i) for oral use.(ii) for topical use.Leflunomide.Lenalidomide:(i) for oral use.(ii) for topical use.Levocabastine.Misoprostol.SitaxentanThalidomide:(i) for oral use.(ii) for topical use.Tretinoin:(i) for oral use.(ii) for topical use.
Column 2Warning statement7, 62 and 7662 and 777, 62 and 7662 and 777, 62 and 767, 62 and 7662 and 777, 62 and 76677, 62 and 7662 and 777, 62 and 7662 and 777, 62 and 877, 62 and 7662 and 7762537, 62 and 767, 62 and 7662 and 777, 62 and 7662 and 77
Endnotes
Note: Endnote 1—About the endnotes
The endnotes provide details of the history of this legislation and its provisions. The following endnotes are included in each compilation:
Endnote 1—About the endnotes
Endnote 2—Abbreviation key
Endnote 3—Legislation history
Endnote 4—Amendment history
Endnote 5—Uncommenced amendments
Endnote 6—Modifications
Endnote 7—Misdescribed amendments
Endnote 8—Miscellaneous
If there is no information under a particular endnote, the word “none” will appear in square brackets after the endnote heading.
Abbreviation key—Endnote 2
The abbreviation key in this endnote sets out abbreviations that may be used in the endnotes.
Legislation history and amendment history—Endnotes 3 and 4
Amending laws are annotated in the legislation history and amendment history.
The legislation history in endnote 3 provides information about each law that has amended the compiled law. The information includes commencement information for amending laws and details of application, saving or transitional provisions that are not included in this compilation.
The amendment history in endnote 4 provides information about amendments at the provision level. It also includes information about any provisions that have expired or otherwise ceased to have effect in accordance with a provision of the compiled law.
Uncommenced amendments—Endnote 5
The effect of uncommenced amendments is not reflected in the text of the compiled law, but the text of the amendments is included in endnote 5.
Modifications—Endnote 6
If the compiled law is affected by a modification that is in force, details of the modification are included in endnote 6.
Misdescribed amendments—Endnote 7
An amendment is a misdescribed amendment if the effect of the amendment cannot be incorporated into the text of the compilation. Any misdescribed amendment is included in endnote 7.
Miscellaneous—Endnote 8
Endnote 8 includes any additional information that may be helpful for a reader of the compilation.
Note: Endnote 2—Abbreviation key
ad = added or inserted
pres = present
am = amended
prev = previous
c = clause(s)
(prev) = previously
Ch = Chapter(s)
Pt = Part(s)
def = definition(s)
r = regulation(s)/rule(s)
Dict = Dictionary
Reg = Regulation/Regulations
disallowed = disallowed by Parliament
reloc = relocated
Div = Division(s)
renum = renumbered
exp = expired or ceased to have effect
rep = repealed
hdg = heading(s)
rs = repealed and substituted
LI = legislative instrument
s = section(s)
LIA = Legislative Instruments Act 2003
Sch = Schedule(s)
mod = modified/modification
Sdiv = Subdivision(s)
No = Number(s)
SLI = Select Legislative Instrument
o = order(s)
SR = Statutory Rules
Ord = Ordinance
Sub-Ch = Sub-Chapter(s)
orig = original
SubPt = Subpart(s)
par = paragraph(s)/subparagraph(s)
/sub-subparagraph(s)
Note: Endnote 3—Legislation history
Name
FRLI registration
Commencement
Application, saving and transitional provisions
Poisons Standard 2010
27/8/2010 (see F2010L02386)
1/9/2010 except items in S.3(2) commencing 1/1/2011
—
Poisons Standard Amendment No. 2 of 2010
17/12/2010 (seeF2010L03274)
1/1/2011
—
Poisons Standard Amendment No. 1 of 2011
27/5/2011 (seeF2011L00873)
1/6/2011
—
Poisons Standard Amendment No. 2 of 2011
7/7/2011 (seeF2011L01435)
8/7/2011
—
Note: Endnote 4—Amendment history
Provision affected
How affected
Part 1, Interpretation,subparagraph 1(1)
am F2010L03274
Part 2, Labels and Containers
am F2010L02386
Part 4, Schedule 2
am F2011L00873
Part 4, Schedule 4
am F2010L03274; am F2011L00873
Part 4, Schedule 6
am F2010L02386
Part 4, Schedule 7
am F2010L02386
Part 4, Schedule 8
am F2010L03274
Part 4, Schedule 9
am F2011L01435
Part 5, Appendix E,Part 2
am F2010L02386; am F2010L03274
Part 5, Appendix F
am F2010L02386
Part 5, Appendix H
am F2011L00873
Note: Endnote 5—Uncommenced amendments – [None]
Note: Endnote 6—Modifications – [None]
Note: Endnote 7—Misdescribed amendments – [None]
Note: Endnote 8—Miscellaneous – [None]
Additional labelling requirements for ce Additional labelling requirements for certain human medicines
Additional labelling requirements for certain human medicines
(See Part 2 Sub-paragraph 14(2))
Medicines required to be labelled with c Medicines required to be labelled with certain warning statements
Medicines required to be labelled with certain warning statements
A substance listed in Column 1 of the following table must be labelled with the warning statement in Appendix F, Part 1 as specified opposite in Column 2.
Column 1substanceAcitretin:(i) for oral use.(ii) for topical use.Adapalene:(i) for oral use.(ii) for topical use.Ambrisentan.Bexarotene:(i) for oral use.(ii) for topical use.Bosentan.Dienestrol.Etretinate:(i) for oral use.(ii) for topical use.Isotretinoin:(i) for oral use.(ii) for topical use.Leflunomide.Lenalidomide:(i) for oral use.(ii) for topical use.Levocabastine.Misoprostol.SitaxentanThalidomide:(i) for oral use.(ii) for topical use.Tretinoin:(i) for oral use.(ii) for topical use.
Column 2Warning statement7, 62 and 7662 and 777, 62 and 7662 and 777, 62 and 767, 62 and 7662 and 777, 62 and 76677, 62 and 7662 and 777, 62 and 7662 and 777, 62 and 877, 62 and 7662 and 7762537, 62 and 767, 62 and 7662 and 777, 62 and 7662 and 77
Endnotes
Note: Endnote 1—About the endnotes
The endnotes provide details of the history of this legislation and its provisions. The following endnotes are included in each compilation:
Endnote 1—About the endnotes
Endnote 2—Abbreviation key
Endnote 3—Legislation history
Endnote 4—Amendment history
Endnote 5—Uncommenced amendments
Endnote 6—Modifications
Endnote 7—Misdescribed amendments
Endnote 8—Miscellaneous
If there is no information under a particular endnote, the word “none” will appear in square brackets after the endnote heading.
Abbreviation key—Endnote 2
The abbreviation key in this endnote sets out abbreviations that may be used in the endnotes.
Legislation history and amendment history—Endnotes 3 and 4
Amending laws are annotated in the legislation history and amendment history.
The legislation history in endnote 3 provides information about each law that has amended the compiled law. The information includes commencement information for amending laws and details of application, saving or transitional provisions that are not included in this compilation.
The amendment history in endnote 4 provides information about amendments at the provision level. It also includes information about any provisions that have expired or otherwise ceased to have effect in accordance with a provision of the compiled law.
Uncommenced amendments—Endnote 5
The effect of uncommenced amendments is not reflected in the text of the compiled law, but the text of the amendments is included in endnote 5.
Modifications—Endnote 6
If the compiled law is affected by a modification that is in force, details of the modification are included in endnote 6.
Misdescribed amendments—Endnote 7
An amendment is a misdescribed amendment if the effect of the amendment cannot be incorporated into the text of the compilation. Any misdescribed amendment is included in endnote 7.
Miscellaneous—Endnote 8
Endnote 8 includes any additional information that may be helpful for a reader of the compilation.
Note: Endnote 2—Abbreviation key
ad = added or inserted
pres = present
am = amended
prev = previous
c = clause(s)
(prev) = previously
Ch = Chapter(s)
Pt = Part(s)
def = definition(s)
r = regulation(s)/rule(s)
Dict = Dictionary
Reg = Regulation/Regulations
disallowed = disallowed by Parliament
reloc = relocated
Div = Division(s)
renum = renumbered
exp = expired or ceased to have effect
rep = repealed
hdg = heading(s)
rs = repealed and substituted
LI = legislative instrument
s = section(s)
LIA = Legislative Instruments Act 2003
Sch = Schedule(s)
mod = modified/modification
Sdiv = Subdivision(s)
No = Number(s)
SLI = Select Legislative Instrument
o = order(s)
SR = Statutory Rules
Ord = Ordinance
Sub-Ch = Sub-Chapter(s)
orig = original
SubPt = Subpart(s)
par = paragraph(s)/subparagraph(s)
/sub-subparagraph(s)
Note: Endnote 3—Legislation history
Name
FRLI registration
Commencement
Application, saving and transitional provisions
Poisons Standard 2010
27/8/2010 (see F2010L02386)
1/9/2010 except items in S.3(2) commencing 1/1/2011